PR Newswire Clinical TrialsOriginal article
Altesa BioSciences Named Recipient of the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the Year
Positive
AI Analysis
Summary
Altesa BioSciences completed an oversubscribed $75 million Series B financing round and received the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the Year. The Atlanta-based clinical-stage company is developing breakthrough therapies targeting chronic lung diseases.
Outcome Details
oversubscribed $75 million Series B financing
Importance:5/10
Sentiment:
0.70
financingSeries Bclinical-stagelung diseaseaward
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 25, 2026 11:00 AM